BIOCRYST PHARMACEUTICALS INC (BCRX)
Biological Products, (No Diagnostic Substances)
Latest Price
$8.23
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
--
P/B Ratio
--
Valuation metrics
adjust assumptions →EPS: $1.21
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$18.15
+121% upside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 23.89M | $238.0M | 9.36% | +1.24M | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 15.83M | $158.0M | 6.20% | -- | 2026-06-30 |
| STATE STREET CORP | 15.19M | $151.0M | 5.95% | +2.98M | 2026-06-30 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 15.10M | $150.0M | 5.91% | +58.4K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.36M | $113.0M | 4.45% | +228.5K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11.14M | $111.0M | 4.36% | -105.5K | 2026-06-30 |
| TCG Crossover Management, LLC | 11.02M | $110.0M | 4.32% | -- | 2026-06-30 |
| PERCEPTIVE ADVISORS LLC | 10.31M | $103.0M | 4.04% | +2.87M | 2026-06-30 |
| Jupiter Topco LLC | 9.54M | $95.0M | 3.74% | -- | 2026-06-30 |
| Vestal Point Capital, LP | 8.30M | $83.0M | 3.25% | +1.27M | 2026-06-30 |